Literature DB >> 20822491

Epigenetic regulation of cell life and death decisions and deregulation in cancer.

Nabil Hajji1, Bertrand Joseph.   

Abstract

For every cell, there is a time to live and a time to die. It is apparent that cell life and death decisions are taken by individual cells based on their interpretation of physiological or non-physiological stimuli, or their own self-assessment of internal damage or changes in their environment. Apoptosis or programmed cell death is a key regulator of physiological growth control and regulation of tissue homoeostasis. One of the most important advances in cancer research in recent years is the recognition that cell death, mostly by apoptosis, is crucially involved in the regulation of tumour formation and also critically determines treatment response. The initiation and progression of cancer, traditionally seen as a genetic disease, is now realized to involve epigenetic abnormalities along with genetic alterations. The study of epigenetic mechanisms in cancer, such as DNA methylation, histone modifications and microRNA expression, has revealed a plethora of events that contribute to the neoplastic phenotype through stable changes in the expression of genes critical to cell death pathways. A better understanding of the epigenetic molecular events that regulate apoptosis, together with the reversible nature of epigenetic aberrations, should contribute to the emergence of the promising field of epigenetic therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20822491     DOI: 10.1042/bse0480121

Source DB:  PubMed          Journal:  Essays Biochem        ISSN: 0071-1365            Impact factor:   8.000


  5 in total

Review 1.  Epigenetic Deregulation of Apoptosis in Cancers.

Authors:  Ezgi Ozyerli-Goknar; Tugba Bagci-Onder
Journal:  Cancers (Basel)       Date:  2021-06-27       Impact factor: 6.639

2.  Immunomodulatory Effects of (R)-Sulforaphane on LPS-Activated Murine Immune Cells: Molecular Signaling Pathways and Epigenetic Changes in Histone Markers.

Authors:  Manuel Alcarranza; Isabel Villegas; Rocío Muñoz-García; Rocío Recio; Inmaculada Fernández; Catalina Alarcón-de-la-Lastra
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-04

Review 3.  Radioresistance in rhabdomyosarcomas: Much more than a question of dose.

Authors:  Simona Camero; Matteo Cassandri; Silvia Pomella; Luisa Milazzo; Francesca Vulcano; Antonella Porrazzo; Giovanni Barillari; Cinzia Marchese; Silvia Codenotti; Miriam Tomaciello; Rossella Rota; Alessandro Fanzani; Francesca Megiorni; Francesco Marampon
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

4.  BATF3 programs CD8+ T cell memory.

Authors:  Marco A Ataide; Karl Komander; Konrad Knöpper; Annika E Peters; Hao Wu; Sarah Eickhoff; Tea Gogishvili; Justus Weber; Anika Grafen; Axel Kallies; Natalio Garbi; Hermann Einsele; Michael Hudecek; Georg Gasteiger; Michael Hölzel; Martin Vaeth; Wolfgang Kastenmüller
Journal:  Nat Immunol       Date:  2020-09-28       Impact factor: 25.606

5.  (-)-Methyl-Oleocanthal, a New Oleocanthal Metabolite Reduces LPS-Induced Inflammatory and Oxidative Response: Molecular Signaling Pathways and Histones Epigenetic Modulation.

Authors:  Tatiana Montoya; Catalina Alarcón-de-la-Lastra; María Luisa Castejón; Juan Ortega-Vidal; Joaquín Altarejos; Marina Sánchez-Hidalgo
Journal:  Antioxidants (Basel)       Date:  2021-12-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.